• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Evinacumab lowers LDL in homozygous familial hypercholesterolemia patients

byHarsh ShahandDeepti Shroff Karhade
August 21, 2020
in Cardiology, Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia.

2. Patients receiving evinacumab did not demonstrate additional serious adverse events compared to the control group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Homozygous familial hypercholesterolemia occurs due to a loss-of-function variant in the low-density lipoprotein (LDL) receptor resulting in low hepatic clearance of LDL cholesterol from the circulation. Patient with the disease have an increased risk of premature atherosclerotic cardiovascular disease. Current treatment options include multiple lipid-lowering drugs and LDL apheresis. However, the interventions are often ineffective in reaching guideline-recommended LDL levels. Therefore, a human monoclonal antibody called evinacumab has been developed to inhibit angiopoietin-like 3, which increases the levels of triglycerides and other lipids. This study evaluated the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia. The results of the study demonstrated that evinacumab significantly lowered LDL cholesterol levels compared to the placebo group. This randomized trial was limited by its short treatment duration, which was not sufficient to determine its long-term safety and cardiovascular outcomes.

Click to read the study in NEJM

Relevant Reading: Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia

In-Depth [randomized controlled trial]: This phase 2, open-label, randomized control trial enrolled 65 participants in a multicenter study at 30 sites in 11 countries. Participants included in the study were 12 years of age or older with at least a 70 milligram per deciliter LDL cholesterol level. Participants presenting with side effects from lipid-lowering therapy were excluded from this study. Patients were randomized in a 2:1 ratio to receive intravenous infusions of evinacumab or placebo treatments, respectively. The primary outcome was the percentage change in LDL level from baseline to week 24. At the end of the follow-up period, participants in the evinacumab group had a 47.1% reduction in LDL cholesterol levels from baseline compared to a 1.9% increase in the control group (between-group least-squares mean difference, -49.0 percentage points; 95% confidence interval [CI] , -65.0 to -33.1; P<0.001). Furthermore, the participants in the evinacumab group had significantly lower levels of apolipoprotein B group (between-group least-squares mean difference, -36.9 percentage points; 95% CI, -48.6 to -25.2; P<0.001), non-HDL cholesterol (between-group least-squares mean difference, -51.7 percentage points; 95% CI, -64.8 to -38.5; P<0.001), and total cholesterol (between-group least-squares mean difference, -48.4 percentage points; 95% CI, -58.7 to -38.1; P<0.001) compared to the placebo group. Finally, adverse events occurred in 66% of the participants in the evinacumab group compared to 81% of the participants in the control group. The study reported an increase in alanine or aspartate aminotransferase for 5% of the participants in the evinacumab group compared to 10% of the participants in the control group. Overall, none of the participants met the criteria for drug-induced liver injury. Taken together, evinacumab significantly lowered LDL cholesterol levels in patients with homozygous familial hypercholesterolemia without increasing adverse event rates.

RELATED REPORTS

#VisualAbstract: Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19

Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19

Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: evinacumabfamilial hypercholesterolemiaLDLmonoclonal antibody
Previous Post

Use of drug-coated balloons for treatment of stenotic lesions in arteriovenous fistulas

Next Post

Diet and gastric bypass have similar metabolic benefits in diabetic patients

RelatedReports

#VisualAbstract: Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19
StudyGraphics

#VisualAbstract: Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19

March 3, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Infectious Disease

Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19

February 22, 2022
Autoantibodies may precede symptom onset in Sjögren’s Syndrome
Chronic Disease

Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome

January 26, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

November 16, 2021
Next Post

Diet and gastric bypass have similar metabolic benefits in diabetic patients

Compression therapy may lower recurrent cellulitis in patients with chronic leg edema

Compression therapy may lower recurrent cellulitis in patients with chronic leg edema

#VisualAbstract: The Portico aortic valve shows non-inferiority to commercially available valves (PORTICO IDE)

#VisualAbstract: The Portico aortic valve shows non-inferiority to commercially available valves (PORTICO IDE)

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.